If I’d Invested $100 in WEED Stock at the Start of 2022, Here’s What I’d Have Now

Shares of Canopy Growth (TSX:WEED) stock are down 70% in 2022. Despite the pullback, it remains a high-risk investment.

| More on:
Cannabis smoke

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s premium investing services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn moresdf

Canadian cannabis stocks have been trailing the broader markets ever since the country legalized marijuana for recreational use. Prior to legalization in October 2018, these pot stocks generated astonishing returns for investors.

For example, shares of Canopy Growth (TSX:WEED)(NASDAQ:CGC) gained 2,360% between October 2015 and October 2018. In the last four years, WEED has lost close to 96% in market value, and WEED stock is currently trading 70% lower in 2022.

So, if I’d invested $100 in WEED stock at the start of 2022, my investment would be worth $29.35 today. Given the significant pullback in Canopy Growth, let’s see if the stock is worth buying right now.

Is Canopy Growth a good stock to buy?

Backed by Constellation Brands, Canopy Growth is among the largest cannabis producers in Canada. In 2018, Constellation Brands pumped in $4 billion for a 38.6% share in Canopy Growth, valuing the latter at $10.4 billion. Now, Canopy Growth is valued at a market cap of $1.6 billion and ended the June quarter with a cash balance of $1.2 billion.

Similar to its Canadian peers, Canopy Growth has burnt billions of dollars in recent years while it increased manufacturing capacity at an exponential rate and aimed to grow inorganically via acquisitions.

However, the slower-than-expected rollout of retail cannabis stores in Canada, a thriving black market, and rising competition resulted in high inventory levels and falling profit margins for most cannabis producers.

Canopy Growth continues to struggle and is wrestling to maintain its market share in a highly competitive and low-cost environment. In the June quarter, net sales fell 19% year over year to $110.1 million. In the last three years, sales have fallen by 8%, making investors nervous.

The company explained it is intentionally reducing sales of its lower-priced products to boost the bottom line and turn profitable in the near future. Analysts expect Canopy’s sales to fall by 8.3% to $477.3 million in fiscal 2023 (ending in March) before rising 11.5% to $532 million in fiscal 2024. The cannabis producer reported record sales of $547 million in fiscal 2021.

What’s next for WEED stock and investors?

While Canopy Growth was rapidly expanding, investors expected the company to benefit from economies of scale and turn profitable by the end of fiscal 2023. However, it is now a loss-making company struggling to grow its revenue.

In the June quarter, Canopy’s net losses totaled $2.1 billion on the back of a $1.7 billion goodwill impairment charge. Additionally, gross margins are negative, and its operating loss stood at $106 million this June.

Investors are betting on the legalization of marijuana at the federal level in the U.S. to act as a key driver of growth for Canopy Growth and other Canadian licenced producers. The United States is a multi-billion-dollar cannabis market. Canopy has a pending deal with Acreage Holdings (a U.S.-based multi-state marijuana producer). Canopy is all set to start distributing its products once pot is legalized south of the border.

Nonetheless, several other cannabis producers in the U.S. already have a huge presence in states where cannabis is legal, suggesting it will be difficult for Canopy to gain traction here.

Investing in WEED stock remains a high-risk proposition due to its weak balance sheet and a challenging macro environment, despite trading at a depressed multiple in 2022.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Aditya Raghunath has no position in any of the stocks mentioned. The Motley Fool recommends Constellation Brands. The Motley Fool has a disclosure policy.

More on Cannabis Stocks

Cannabis smoke
Cannabis Stocks

Canopy Growth Stock: Is Now a Good Time to Invest?

The road ahead is highly uncertain for Canopy Growth, as the stock is plagued with losses and seemingly unsurmountable industry…

Read more »

Cannabis grows at a commercial farm.
Cannabis Stocks

TLRY Stock: Should You Invest Now?

TLRY is a Canadian cannabis stock which is trading 91% below record highs. Let's see if you should own TLRY…

Read more »

Cannabis grows at a commercial farm.
Cannabis Stocks

Is Tilray Stock a Buy in February 2023?

Despite the volatile cannabis sector, Tilray could be a superb buy for long-term investors.

Read more »

Young woman sat at laptop by a window
Cannabis Stocks

Is SNDL Stock a Buy in February 2023?

SNDL is a beaten-down cannabis stock. While its revenue growth is exceptional, a weak balance sheet has driven stock prices…

Read more »

A cannabis plant grows.
Cannabis Stocks

TLRY Stock: Here’s What’s Coming in 2023

Tilray Inc. (TSX:TLRY) is geared up for big growth this decade and looks like one of the top cannabis stocks…

Read more »

A person holds a small glass jar of marijuana.
Cannabis Stocks

Canopy Growth Stock: Here’s What’s Coming in 2023

Canopy Growth stock has made a lot of new moves in the last few months, but where is the company…

Read more »

A cannabis plant grows.
Cannabis Stocks

Better Cannabis Buy: Canopy Growth Stock or Tilray?

Only two TSX weed stocks can deliver substantial returns in the highly anticipated growth of the global cannabis market.

Read more »

Medicinal research is conducted on cannabis.
Cannabis Stocks

Is Tilray Stock a Buy in January 2023?

Tilray stock has lost 50% of its value in the last 12 months, in line with its peers.

Read more »